Analysts are divided on Editas Medicine's performance, with ...
Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.
Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment